Menu

Study: Infants’ Brain Activity Patterns Predict Autism Risk

Scientists provide evidence that blood-flow patterns in six-month-old babies’ brains can accurately predict cognitive and behavioral markers of autism spectrum disorder two years later.  

Jun 8, 2017
Aggie Mika

PIXABAY, BRIEFKASTEN2

  Using functional magnetic resonance imaging (fMRI), researchers demonstrated that six-month-old infants previously identified as high risk for autism spectrum disorder (ASD) displayed brain activity patterns that predicted their future diagnosis with the condition, according to a report published today (June 7) in Science Translational Medicine.

In a collaborative effort, scientists at the University of North Carolina at Chapel Hill and Washington University School of Medicine scanned the brains of 59 sleeping infants using fMRI—a non-invasive imaging technique that picks up on changes in brain function based on fluctuations in blood flow throughout the brain. The babies included in the study had siblings already diagnosed with ASD. According to Spectrum, infants with older ASD siblings have “about a 20-fold increase in autism risk compared with the general population.”

When the kids in the study reached two years of age, the researchers assessed their sociability, language and motor development, ability to communicate, and propensity to engage in ASD-like repetitive behavior. At this time, 11 out of the 59 toddlers had been diagnosed with ASD. The researchers asked if the activity patterns in functionally connected brain regions at six months could identify which toddlers would display cognitive and behavioral traits indicative of an ASD diagnosis—the researchers refer to this in their study as “a research clinical best-estimate diagnosis of ASD.”

The researchers found that babies’ brain activity patterns indeed correlated with repetitive and social behavior as well as motor and language abilities later in life. Using a machine learning algorithm, the scientists demonstrated that brain activity in early life correctly predicted an ASD diagnosis in nine out of 11 babies, and correctly predicted the lack of ASD in all 48 infants who did not receive a diagnosis.

According to the National Institute of Child Health and Human Development (NICHD), typical ASD symptoms include problems with "communication and interactions with other people" and engaging in "routines or repetitive behaviors."

Doctors are seldom able to diagnose ASD prior to two years of age because “behavioral characteristics of ASD generally unfold during the second year of life, typically showing consolidation of the full behavioral syndrome by about 24 months of age,” the authors write in the report.

“Autism is defined as a collection of behaviors, but infants don’t really have those behaviors,” lead author Robert Emerson of the University of North Carolina at Chapel Hill tells Spectrum. “What we’ve gone to look for is the foundations in the brain that set those behaviors up in the future.”

“Although the findings are early-stage, the study suggests that in the future, neuroimaging may be a useful tool to diagnose autism or help health care providers evaluate a child’s risk of developing the disorder,” says National Institute of Mental Health (NIMH) director Joshua Gordon in a news release.

Gordon is not listed as an author on the report. The authors were funded by NIMH and NICHD. 

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.